Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Vascular disorders – page 32

  • 846 clinical trials
  • 351 recruiting
  • 382 conditions
  • 28 countries

Conditions in this area

382 conditions with trials, the busiest first

Ischaemic stroke52Migraine48Pulmonary arterial hypertension41Systemic scleroderma40Coronary artery disease37Arteriosclerosis32Acute myocardial infarction30Hypertension29Pulmonary hypertension24Acute coronary syndrome21Giant cell arteritis18Paroxysmal nocturnal haemoglobinuria17Peripheral arterial occlusive disease17Septic shock17Cardiovascular disorder16Subarachnoid haemorrhage16Acute respiratory distress syndrome15Atrial fibrillation15Anti-neutrophil cytoplasmic antibody positive vasculitis14Cerebrovascular accident14Pulmonary embolism14Embolism13Myocardial infarction13Diabetic foot12+358

Clinical trials in Vascular disorders

846 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

846 clinical trials

Intracranial aneurysm

Not yet recruiting

Comparing two heparin sodium doses on silent brain lesions in patients undergoing embolization of unruptured intracranial aneurysm with drug combination

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Centre Hospitalier Universitaire De Bordeaux

Embolism venous

Not yet recruiting

Safety, Tolerability and Effect of RBD4059 Injection in Adults with Prior VTE After Anticoagulant Therapy and Cancer Patients at High Risk of VTE

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:RBD4059
  • Sponsor:Ribocure Pharmaceuticals AB

Pulmonary embolism

Not yet recruiting

Reduced-dose versus full-dose alteplase for high-risk acute pulmonary embolism patients: a randomized multicenter trial

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:University Of Gothenburg

Cerebrovascular accident

Not yet recruiting

Effect of baclofen, gabapentin and oxazepam on brain plasticity and motor learning in subacute stroke patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Baclofen
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Skin ulcer

Not yet recruiting

Safety and Efficacy of EscharEx (concentrate of proteolytic enzymes enriched in bromelain) in Adults with Venous Leg Ulcers

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Concentrate of proteolytic enzymes enriched in bromelain
  • Sponsor:Mediwound Ltd.

Optic ischaemic neuropathy

Not yet recruiting

Efficacy and Safety of Intranasal Cenegermin in Adults with Non‑Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Subarachnoid haemorrhage+4

Not yet recruiting

Prehospital Sedation with Esketamine versus Propofol in Patients with Severe Acute Brain Injury

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Propofol
  • Sponsor:Rigshospitalet

Acromegaly

Not yet recruiting

Short-Acting Pasireotide Test to Predict Treatment Response in Patients with Acromegaly

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pasireotide
  • Sponsor:Instituto De Investigacion En Ciencias De La Salud Germans Trias I Pujol

Pulmonary hypertension

Not yet recruiting

Discontinuing vs Continuing Riociguat in Chronic Thromboembolic Pulmonary Hypertension Patients After Successful Balloon Pulmonary Angioplasty

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Riociguat
  • Sponsor:Assistance Publique Hopitaux De Paris

Ischaemic stroke

Not yet recruiting

Effectiveness of Tenecteplase in Acute Ischemic Stroke Patients Treated 4.5–24 Hours After Onset Before Transfer for Thrombectomy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tenecteplase
  • Sponsor:Fondation A De Rothschild

Overweight+1

Not yet recruiting

Effect of bupropion hydrochloride and mushroom supplement on body weight in overweight adults: a 52‑week randomized trial

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Bupropion Hydrochloride
  • Sponsor:Uppsala University

Malformation venous

Not yet recruiting

Surgery versus Lauromacrogol 400 injection for superficial labial venous malformations in children and adults: a randomized controlled trial

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lauromacrogol 400
  • Sponsor:Centre Hospitalier Regional Universitaire De Tours

Substances studied in this area

The therapies tested most often in Vascular disorders trials.

Acetylsalicylic Acid59 clinical trialsSodium Chloride55 clinical trialsClopidogrel33 clinical trialsApixaban28 clinical trialsTicagrelor28 clinical trialsRivaroxaban21 clinical trialsAtorvastatin17 clinical trialsPrasugrel17 clinical trialsRituximab16 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.